
Shares of Trevi Therapeutics TRVI.O down 3.6% in extended trading to $6.09 as co plans equity raise
New Haven, Connecticut-based firm commences $100 mln stock offering
Morgan Stanley. Leerink, Stifel and Cantor are jt bookrunners
Before the bell on Mon, co announced positive topline results from Phase II trial of its therapy, Haduvio, for patients with a type of chronic cough, and said plans Phase III initiation in 2026
With ~101.7 mln shares outstanding, co has about $680 market cap, per LSEG data
TRVI closed down 3% at $6.32 on Mon, trimming YTD gain to 53%